Quick Answer
Jade Biosciences, Inc. reported Cash and Equivalents of $88.44 million for fiscal year 2025.
Jade Biosciences, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $88.44M | +27.5% |
| 2024 | $69.39M | +195.4% |
| 2023 | $23.49M | +4.9% |
| 2022 | $22.40M | -58.7% |
| 2021 | $54.20M | +1085.2% |
| 2020 | $4.57M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $50.11M | +61.0% | -77.3% |
| June 30, 2025 | $220.94M | +611.1% | +399.6% |
| March 31, 2025 | $44.22M | +384.8% | -36.3% |
| December 31, 2024 | $69.39M | +195.4% | +123.0% |
| September 30, 2024 | $31.11M | -3.3% | +0.1% |
| June 30, 2024 | $31.07M | -49.0% | +240.6% |
| March 31, 2024 | $9.12M | -65.7% | -61.2% |
| December 31, 2023 | $23.49M | +4.9% | -27.0% |
- Jade Biosciences, Inc. showed an increase of +27.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Jade Biosciences, Inc.’s cash and equivalents has grown by 1833.9% (from $4.57 million to $88.44 million).
- The most recent figure is from Jade Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: